-
1Academic Journal
Authors: E. A. Kasparova, N. R. Marchenko, Е. А. Каспарова, Н. Р. Марченко
Source: Ophthalmology in Russia; Том 19, № 1 (2022); 38-45 ; Офтальмология; Том 19, № 1 (2022); 38-45 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2022-1
Subject Terms: фактор роста нервов, neurotrophic keratopathy, corneal erosion, corneal ulcer, neurogenic inflammation, corneal melting, corneal nerves, nerve growth factor, нейротрофическая кератопатия, эрозия роговицы, язва роговицы, нейрогенное воспаление, расплавление роговицы, нервы роговицы
File Description: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/1768/932; Dua H.S., Said D.G., Messmer E.M., Rolando M., Benitez-Del-Castillo J.M., Hossain P.N., Shortt A.J., Geerling G., Nubile M., Figueiredo F.C., Rauz S., Mastropasqua L., Rama P., Baudouin C. Neurotrophic keratopathy. Prog. Retin. Eye Res. 2018 Sep;66:107–131. DOI:10.1016/j.preteyeres.2018.04.003; Muller L.J., Marfurt C.F., Kruse F., Tervo T.M. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521–542.; Sigelman S., Friedenwald J.S. Mitotic and wound healing activities of the corneal epithelium: effect of sensory denervation. Arch Ophthalmol. 1954;52:46–57.; Simone S. De ricerche sul contenuto in acqua totale ed in azoto totale della cornea di coniglio in condizione di cheratite neuroparalitica sperimentale. Arch Ottalmol. 1958;62:151.; Mackie I.A. Neuroparalytic keratitis. In: Fraunfelder F., Roy F.H., Meyer S.M., editors. Current Ocular Therapy. Philadelphia, PA, USA: WB Saunders; 1995.; Sacchetti M., Lambiase A., Diagnosis and management of neurotrophic keratitis. Clin. Ophthalmol. 2014;8:571–579. DOI:10.2147/OPTH.S45921; Labetoulle M., Auquier P., Conrad H., Crochard A., Daniloski M., Bouee S., El Hasnaoui A., Colin J. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112:888–895.; Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., Betts R.F., Gershon A.A., Haanpaa M.L., McKendrick M.W., Nurmikko T.J., Oaklander A.L., Oxman M.N., Pavan-Langston D., Petersen K.L., Rowbotham M.C., Schmader K.E., Stacey B.R., Tyring S.K., van Wijck A.J., Wallace M.S., Wassilew S.W., Whitley R.J. Recommendations for the management of herpes zoster. Clin. Infect. Dis. 2007;44 (Suppl. 1):S1–S26.; Bhatti M.T., Patel R. Neuro-ophthalmic considerations in trigeminal neuralgia and its surgical treatment. Curr. Opin. Ophthalmol. 2005;16:334–340.; Azuma M., Yabuta C., Fraunfelder F.W., Shearer T.R. Dry Eye in LASIK Patients, BMC Res Notes. 2014;7:420. DOI:10.1186/1756-0500-7-420; Versura P., Giannaccare G., Pellegrini M., Sebastiani S., Campos E.C. Neurotrophic keratitis: current challenges and future prospects. Eye Brain. 2018;10:37–45. DOI:10.2147/EB.S117261; Hamrah P., Cruzat A., Dastjerdi M.H., Zheng L., Shahatit B.M., Bayhan H.A., Dana R. Pavan-Langston Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2010;117(10):1930–1936. DOI:10.1016/j.ophtha.2010.07.010; Lee B.H., McLaren J.W., Erie J.C., Hodge D.O., Bourne W.M. Reinnervation in the cornea after LASIK. Invest Ophthalmol Vis Sci. 2002;43(12):3660–3664.; Semeraro F., Forbice E., Romano V. Neurotrophic keratitis. Ophthalmologica. 2014;231(4):191–197. DOI:10.1159/000354380; Каспарова Евг.А., Каспаров А.А., Собкова О.И., Каспарова Ел.А., Розинова В.Н. Способ лечения гнойной язвы роговицы, развившейся на глазах с нейротрофическим кератитом и лагофтальмом. Вестник офтальмологии. 2019;135(5) ч. 2:220–225. DOI:10.17116/oftalma2019135052220; Tavakoli M., Marshall A., Pitceathly R. Corneal confocal microscopy: a novel means to detect nerve fibre damage in idiopathic small fibre neuropathy. Exp Neurol. 2010;223(1):245–250. DOI:10.1016/j.expneurol.2009.08.033; Аветисов С.Э., Черненкова Н.А., Cурнина З.В., Ахмеджанова Л.Т., Фокина А.С., Строков И.А. Возможности ранней диагностики диабетической полинейропатии на основе исследования нервных волокон роговицы. Вестник офтальмологии 2020;136(5):155–162. DOI:10.17116/oftalma2020136052155; Banerjee P.J., Chandra A., Sullivan P.M., Charteris D.G. Neurotrophic corneal ulceration after retinal detachment surgery with retinectomy and endolaser: a case series. JAMA Ophthalmol. 2014;132(6):750–752. DOI:10.1001/jamaophthalmol.2014.280; Qi H., Chuang E.Y., Yoon K.C., de Paiva C.S., Shine H.D., Jones D.B., Pflugfelder S.C., Li D.Q. Patterned expression of neurotrophic factors and receptors in human limbal and corneal regions. Mol. Vis. 2007;13:1934–1941.; Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154–1162.; Bonini S., Aloe L., Bonini S., Rama P., Lamagna A., Lambiase A. Nerve growth factor (NGF): an important molecule for trophism and healing of the ocular surface. Adv Exp Med Biol. 2002;506(Pt A):531–537. DOI:10.1007/978-1-4615-0717-8_75; Lambiase A., Manni L., Bonini S., Rama P., Micera A., Aloe L. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci. 2000;41(5):1063–1069.; Heigle T.J., Pflugfelder S.C. Aqueous tear production in patients with neurotrophic keratitis. Cornea. 1996;15(2):135–138.; Sacchetti M., Lambiase A. Neurotrophic factors and corneal nerve regeneration. Neural Regen Res. 2017;12(8):1220–1224. DOI:10.4103/1673-5374.213534; Hosoi J., Murphy G.F., Egan C.L., Lerner E.A., Grabbe S., Asahina A., Granstein R.D. Regulation of Langerhans cell function by nerves containing calcitonin generelated peptide. Nature. 1993;363:159–163.; Belmonte C., Acosta M.C., Gallar J. Neural basis of sensation in intact and injured corneas. Exp. Eye Res. 2004;78:513–525. DOI:10.1016/j.exer.2003.09.023; Baudouin C., Aragona P., Messmer E.M., Tomlinson A., Calonge M., Boboridis K.G., Akova Y.A., Geerling G., Labetoulle M., Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul. Surf. 2013;11:246–258. DOI:10.1016/j.jtos.2013.07.003; Fini M.E., Cook J.R., Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch. Dermatol. Res. 1998;290 (Suppl. l):S12–S23.; Mohammed I., Said D.G., Dua H.S. Human antimicrobial peptides in ocular surface defense. Prog. Retin. Eye Res. 2017;61:1–22. DOI:10.1016/j.preteyeres.2017.03.004; Pflugfelder S.C., Farley W., Luo L., Chen L.Z., de Paiva C.S., Olmos L.C., Li D.Q., Fini M.E. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am. J. Pathol. 2005;166:61–71. DOI:10.1016/S0002-9440(10)62232-8; Chotikavanich S., de Paiva C.S., de Li Q., Chen J.J., Bian F., Farley W.J., Pflugfelder S.C. Production and activity of matrix metalloproteinase-9 on the ocularsurface increase in dysfunctional tear syndrome. Invest. Ophthalmol. Vis. Sci. 2009;50:3203–3209. DOI:10.1167/iovs.08-2476; Hamrah P., Cruzat A., Dastjerdi M.H., Prüss H., Zheng L., Shahatit B.M., Bayhan H.A., Dana R., Pavan-Langston D. Unilateral herpes zoster ophthalmicus results inbilateral corneal nerve alteration: an in vivo confocal microscopy study. Ophthalmology 2013;20:40–47. DOI:10.1016/j.ophtha.2012.07.036; Cavalcanti B.M., Cruzat A., Sahin A., Pavan-Langston D., Samayoa E., Hamrah P. In vivo confocal microscopy detects bilateral changes of corneal immune cellsand nerves in unilateral herpes zoster ophthalmicus. Ocul. Surf. 2018;16:101–111. DOI:10.1016/j.jtos.2017.09.004; Yamaguchi T., Turhan A., Harris D.L., Hu K., von Andrian H.P.U., Hamrah P. Bilateral nerve alterations in a unilateral experimental neurotrophic keratopathy model: a lateral conjunctival approach for trigeminal axotomy. PLoS One 2013;14:е70908. DOI:10.1371/journal.pone.0070908; Yamaguchi T., Hamrah P., Shimazaki J. Bilateral alterations in corneal nerves,dendritic cells, and tear cytokine levels in ocular surface disease. Cornea 2016;35(Suppl.1):S65–S70. DOI:10.1097/ICO.0000000000000989; Bonini S., Rama P., Olzi D., Lambiase A. Neurotrophic keratitis. Eye (Lond) 2003;17:989–995.; Alio J.L., Pastor S., Ruiz-Colecha J., Rodriguez A., Artola A. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J Refract Surg. 2007;23(6):617–619.; Ambrósio R. Jr, Tervo T., Wilson S.E. LASIK-associated dry eye and neurotrophic epitheliopathy: pathophysiology and strategies for prevention and treatment. J Refract Surg. 2008;24(4):396–407. DOI:10.3928/1081597X-20080401-14; Bentivoglio A.R., Bressman S.B., Cassetta E., Carretta D., Tonali P., Albanese A. Analysis of blink rate patterns in normal subjects. Mov Disord. 1997;12(6):1028– 1034. DOI:10.1002/mds.870120629; Al-Aqaba M.A., Otri A.M., Fares U., Miri A., Dua H.S. Organization of the regenerated nerves in human corneal grafts. Am J Ophthalmol. 2012;153(1):29–37.e4. DOI:10.1016/j.ajo.2011.06.006; Zabel R., Mintsioulis G. Hyperplastic precorneal membranes. Extending the Spectrum of Neurotrophic Keratitis. Cornea. 1989;8(4):247–250.; Cavanagh H.D., Colley A.M., Pihlaja D,J. Persistent corneal epithelial defects, Int Ophthalmol Clin 1979;19(2):197–206.; Радзиховский Б.Л., Лучик В.И. Чувствительность роговицы и ее диагностическое значение в патологии глаза и организма. Киев: Здоров’я, 1974:11–21.; Golebiowski B., Papas E., Stapleton F. Assessing the sensory function of the ocular surface: implications of use of a non-contact air jet aesthesiometer versus the Cochet-Bonnet aesthesiometer. Exp Eye Res. 2011;92(5):408–413. DOI:10.1016/j.exer.2011.02.016; Belmonte C., Acosta M.C., Schmelz M., Gallar J. Measurement of corneal sensitivity to mechanical and chemical stimulation with a CO2 esthesiometer. Invest Ophthalmol Vis Sci. 1999;40(2):513–519.; Tesón M., Calonge M., Fernández I., Stern M.E., González-García M.J. Characterization by Belmonte’s gas esthesiometer of mechanical, chemical, and thermal corneal sensitivity thresholds in a normal population. Invest Ophthalmol Vis Sci. 2012;53(6):3154–3160. DOI:10.1167/iovs.11-9304; Dhillon V.K., Elalfy M.S., Al-Aqaba M., Gupta A., Basu S., Dua H.S. Corneal hypoesthesia with normal sub-basal nerve density following surgery for trigeminal neuralgia. Acta Ophthalmol. 2016;94(1):e6–10. DOI:10.1111/aos.12697; https://www.ophthalmojournal.com/opht/article/view/1768
-
2Academic Journal
Authors: E. A. Kasparova, N. R. Marchenko, Е. А. Каспарова, Н. Р. Марченко
Source: Ophthalmology in Russia; Том 19, № 2 (2022); 265-271 ; Офтальмология; Том 19, № 2 (2022); 265-271 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2022-2
Subject Terms: невротизация роговицы, neurotrophic keratopathy, persistent epithelial defect, corneal erosion, corneal ulcer, corneal melting, corneal nerves, recombinant nerve growth factor, insulin, neurogenic inflammation, autologous serum, corneal neurotization, нейротрофическая кератопатия, стойкий дефект эпителия, эрозия роговицы, язва роговицы, расплавление роговицы, нервы роговицы, рекомбинантный фактор роста нервов, инсулин, нейрогенное воспаление, аутологичная сыворотка
File Description: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/1842/967; Dua H.S., Said D.G., Messmer E.M., Rolando M., Benitez-Del-Castillo J.M., Hossain P.N., Shortt A.J., Geerling G., Nubile M., Figueiredo F.C., Rauz S., Mastropasqua L., Rama P., Baudouin C. Neurotrophic keratopathy. Prog Retin Eye Res. 2018 Sep;66:107–131. DOI:10.1016/j.preteyeres.2018.04.003; Muller L.J., Marfurt C.F., Kruse F., Tervo T.M. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521–542. [PubMed] [Google Scholar]; Qi H., Chuang E.Y., Yoon K.C., de Paiva C.S., Shine H.D., Jones D.B., Pflugfelder S.C., Li D.Q. Patterned expression of neurotrophic factors and receptors in human limbal and corneal regions. Mol. Vis. 2007;13:1934–1941.; Sigelman S., Friedenwald J.S. Mitotic and wound healing activities of the corneal epithelium: effect of sensory denervation. Arch Ophthalmol. 1954;52:46–57.; Mackie I.A. Neuroparalytic keratitis. In: Fraunfelder F., Roy F.H., Meyer S.M., editors. Current Ocular Therapy. Philadelphia, PA, USA: WB Saunders; 1995.; Каспарова Е.А., Каспаров А.А., Собкова О.И., Каспарова Е.А., Розинова В.Н. Способ лечения гнойной язвы роговицы, развившейся на глазах с нейротрофическим кератитом и лагофтальмом. Вестник офтальмологии. 2019;135(5)2:220–225. DOI:10.17116/oftalma2019135052220; Tai M.C., Cosar C.B., Cohen E.J., Rapuano C.J., Laibson P.R. The clinical efficacy of silicone punctal plug therapy. Cornea 2002;21(2):135–139.; Trinh T., Santaella G., Mimouni M., Mednick Z., Cohen E., Sorkin N., Rootman D.S., Slomovic A.R., Chan C.C. Assessment of response to multimodal management of neurotrophic corneal disease. Ocul Surf. 2021 Jan;19:330–335. DOI:10.1016/j.jtos.2020.11.003; Каспаров А.А. Офтальмогерпес М.: «Медицина», 1984.; Grey F., Carley F., Biswas S., Tromans C. Scleral contact lens management of bilateral exposure and neurotrophic keratopathy. Cont Lens Anterior Eye. 2012 Dec;35(6):288–291. DOI:10.1016/j.clae.2012.07.009; Matsumoto Y., Dogru M., Goto E., Ohashi Y., Kojima T., Ishida R., Tsubota K. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004 Jun;111(6):1115–1120. DOI:10.1016/j.ophtha.2003.10.019; Rao K., Leveque C., Pflugfelder S.C. Corneal nerve regeneration in neurotrophic keratopathy following autologous plasma therapy. Br J Ophthalmol. 2010 May;94(5):584–591. DOI:10.1136/bjo.2009.164780; Aifa A., Gueudry J., Portmann A., Delcampe A., Muraine M. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8181–8185. DOI:10.1167/iovs.12-10476; Arvola R.P., Robciuc A., Holopainen J.M. Matrix Regeneration Therapy: A Case Series of Corneal Neurotrophic Ulcers. Cornea. 2016 Apr;35(4):451–455. DOI:10.1097/ICO.0000000000000759; Giannaccare G., Fresina M., Vagge A., Versura P. Synergistic effect of regenerating agent plus cord blood serum eye drops for the treatment of resistant neurotrophic keratitis: a case report and a hypothesis for pathophysiologic mechanism. Int Med Case Rep J. 2015 Nov 2;8:277–281. DOI:10.2147/IMCRJ.S89968; Nishida T., Chikama T., Morishige N., Yanai R., Yamada N., Saito J. Persistent epithelial defects due to neurotrophic keratopathy treated with a substance pderived peptide and insulin-like growth factor 1. Jpn J Ophthalmol. 2007 NovDec;51(6):442–447. DOI:10.1007/s10384-007-0480-z; Yamada N., Matsuda R., Morishige N., Yanai R., Chikama T.I., Nishida T., Ishimitsu T., Kamiya A. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol. 2008 Jul;92(7):896–900. DOI:10.1136/bjo.2007.130013; Soares R.J., Arêde C., Sousa Neves F., da Silva Fernandes J., Cunha Ferreira C., Sequeira J. Topical Insulin—Utility and Results in Refractory Neurotrophic Keratopathy in Stages 2 and 3. Cornea. September 4, 2021. DOI:10.1097/ICO.0000000000002858; Stuard W.L., Titone R., Robertson D.M. The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease. Front Endocrinol (Lausanne). 2020 Mar 3;11:24. DOI:10.3389/fendo.2020.00024; Deeks E.D., Lamb Y.N. Cenegermin: A Review in Neurotrophic Keratitis. Drugs. 2020 Apr;80(5):489–494. DOI:10.1007/s40265-020-01289-w; Mastropasqua L., Lanzini M., Dua H.S., D’ Uffizi A., Di Nicola M., Calienno R., Bondì J., Said D.G., Nubile M. In Vivo Evaluation of Corneal Nerves and Epithelial Healing After Treatment With Recombinant Nerve Growth Factor for Neurotrophic Keratopathy. Am J Ophthalmol. 2020 Sep;217:278–286. DOI:10.1016/j.ajo.2020.04.036; Di Zazzo A., Varacalli G., Mori T., Coassin M. Long-term restoration of corneal sensitivity in neurotrophic keratopathy after rhNGF treatment. Eur J Ophthalmol. 2020 Aug 27:1120672120953343. DOI:10.1177/1120672120953343; Zwingelberg S.B., Bachmann B.O., Cursiefen C. Real Life Data on Efficacy and Safety of Topical NGF Eye Drops (Cenegermin). Klin Monbl Augenheilkd. 2020 Dec;237(12):1455–1461. English, German. DOI:10.1055/a-1274-3675; Lee Y.C., Kim S.Y. Treatment of neurotrophic keratopathy with nicergoline. Cornea. 2015 Mar;34(3):303–307. DOI:10.1097/ICO.0000000000000348; Cosar C.B., Cohen E.J., Rapuano C.J., Maus M., Penne R.P., Flanagan J.C., Laibson P.R. Tarsorrhaphy: clinical experience from a cornea practice. Cornea. 2001 Nov;20(8):787–791. DOI:10.1097/00003226-200111000-00002; Kirkness C.M., Adams G.G., Dilly P.N., Lee J.P. Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology. 1988 Apr;95(4):473–480. https://doi.org/10.1016/s0161-6420(88)33163-5; Chen H.J., Pires R.T., Tseng S.C. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. 2000 Aug;84(8):826–833. DOI:10.1136/bjo.84.8.826; Khokhar S., Natung T., Sony P., Sharma N., Agarwal N., Vajpayee R.B. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea. 2005 Aug;24(6):654–660. DOI:10.1097/01. ico.0000153102.19776.80; Khodadoust A., Quinter A.P. Microsurgical approach to the conjunctival flap. Arch Ophthalmol. 2003 Aug;121(8):1189–1193. DOI:10.1001/archopht.121.8.1189; Fogle J.A., Kenyon K.R., Foster C.S. Tissue adhesive arrests stromal melting in the human cornea. Am J Ophthalmol. 1980 Jun;89(6):795–802. DOI:10.1016/00029394(80)90168-3; Margo J.A., Jeng B.H. Corneal Transplantation in the Setting of Neurotrophic Keratopathy—Risks and Considerations. Curr Ophthalmol Rep. 2017;5:14–22. DOI:10.1007/s40135-017-0118-3; Каспаров А.А., Каспарова Е.А., Собкова О.И. Лечение центральной язвы роговицы на фоне лагофтальма с помощью аутоконъюнктивальной пластики в сочетании с оптической иридэктомией и наружной блефарорафией (клиническое наблюдение). Вестник офтальмологии. 2010;126(2):35– 37.; Terzis J.K., Dryer M.M., Bodner B.I. Corneal neurotization: a novel solution to neurotrophic keratopathy. Plast Reconstr Surg. 2009 Jan;123(1):112–120. DOI:10.1097/PRS.0b013e3181904d3a; Allevi F., Fogagnolo P., Rossetti L., Biglioli F. Eyelid reanimation, neurotisation, and transplantation of the cornea in a patient with facial palsy. BMJ Case Rep. 2014 Aug 19;2014:bcr2014205372. DOI:10.1136/bcr-2014-205372; Elbaz U., Bains R., Zuker R.M., Borschel G.H., Ali A. Restoration of corneal sensation with regional nerve transfers and nerve grafts: a new approach to a difficult problem. JAMA Ophthalmol. 2014 Nov;132(11):1289–1295. DOI:10.1001/jamaophthalmol.2014.2316; Liu C.Y., Arteaga A.C., Fung S.E., Cortina M.S., Leyngold I.M., Aakalu V.K. Corneal neurotization for neurotrophic keratopathy: Review of surgical techniques and outcomes. Ocul Surf. 2021 Feb 26;20:163–172. DOI:10.1016/j.jtos.2021.02.010; Груша Я.О., Новиков М.Л., Данилов С.С., Фетцер Е.И., Карапетян А.С. Невротизация роговицы как патогенетически направленный метод лечения нейротрофического кератита у пациентов с лицевым параличом. Вестник офтальмологии. 2020;136(5):52–57. DOI:10.17116/oftalma202013605152; https://www.ophthalmojournal.com/opht/article/view/1842
-
3Academic Journal
Authors: A. N. Kucher
Source: Бюллетень сибирской медицины, Vol 19, Iss 2, Pp 171-181 (2020)
Subject Terms: нейрогенное воспаление, генетика, Medicine
Relation: https://bulletin.ssmu.ru/jour/article/view/2874; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b
-
4Academic Journal
Authors: БОБКО С.И., ЦЫКИН А.А.
File Description: text/html
-
5Academic Journal
Authors: A. R. Artemenko, A. L. Kurenkov, S. S. Nikitin, K. B. Belomestova, А. Р. Артеменко, А. Л. Куренков, С. С. Никитин, К. В. Беломестова
Source: Neuromuscular Diseases; № 4 (2013); 6-12 ; Нервно-мышечные болезни; № 4 (2013); 6-12 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2013-0-4
Subject Terms: центральная сенситизация, botulinumtoxin type A, оnabotulinumtoxinA, chemodenervation, antinociceptive effect, antinociceptive mechanism, calcitonin gene-related peptide, neurogenic inflammation, peripheral sensitization, central sensitization, ботулинический токсин типа А, хемоденервация, антиноцицептивное действие, калицитонин-генсвязанный пептид, нейрогенное воспаление, периферическая сенситизация
File Description: application/pdf
Relation: https://nmb.abvpress.ru/jour/article/view/61/57; Артеменко А.Р., Куренков А.Л. Ботулинический токсин: вчера, сегодня, завтра. Нервно-мышечные болезни 2013;2:6–18.; Burgen A., Dickens F., Zatman L. J. The action of botulinum toxin on the neuromusculat junction. J Phisiol 1949;109:10–24.; Aoki K.R., Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011;17(Suppl 1):28–33.; Wheeler A., Smith H.S. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013;06:24–146.; Jabbari B., Machado D. Treatment of Refractory Pain with Botulinum Toxins – An Evidence-Based Review. Pain Med 2011;12(11):1594–606.; Aurora S.K., Dodick D.W., Turkel C.C. et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30 (7):793–803.; Blumenfeld A., Silberstein S.D., Dodick D.W. et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50(9):1406–18.; Cady R.K., Schreiber C.P., Porter J.A. et al. A Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine. Headache 2011;51(1):21–32.; Diener H.C., Dodick D.W., Aurora S.K. et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30 (7):804–14.; Dodick D.W., Turkel C.C., DeGryse R.E. et al. PREEMPT Chronic Migraine Study Group. Onabotulinum toxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921–36.; Lipton R.B., Varon S.F., Grosberg B. et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77(15):1465–72.; Silberstein S.D., Blumenfeld A.M., Cady R.K. et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013;15;331(1–2):48–56.; Headache Classification Commitee of the International Headache Society. The Internetional Classification of Headache Disorders, 3rd edition (beta version), Cephalalgia 2013;33(9):629–808.; Артеменко А.Р. Хроническая мигрень: клиника, патогенез, лечение. Дис. . д-ра мед.наук. М., 2010. 205 с.; Артеменко А.Р., Куренков А.Л. Хроническая мигрень. М.: ИД «АБВ-пресс», 2012. 488 с.; Bigal M.E., Serrano D., Reed M., Lipton R.B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559–66.; Katsarava Z., Dzagnidze A., Kukava M. et al. Primary headache disorders in the Republic of Georgia: Prevalence and risk factors. Neurology 2009;73:1796–803.; Natoli J.L., Manack A., Dean B. et al. Global prevalence of chronic migraine: а systematic review. Cephalalgia 2010;30:599–609.; Reed M.L., Buse D.C., Manack A.N. et al. Prevalence of chronic migraine (CM), headache-related disability and sociodemographic factors in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2011;51:28 [abstr. P58].; Артеменко А.Р., Куренков А.Л., Никитин С.С. Лечение хронической мигрени. Журн неврол и психиатр 2011;111(5):85–9.; Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(Suppl 1):9–15.; Артеменко А.Р., Куренков А.Л. Дисфункция краниоцервикальных мышц при хронической мигрени. Нервно-мышечные болезни 2011;1:51–5.; Cheshire W.P., Abashian S.W., Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59(1):65–9.; Wheeler A.H., Goolkasian P., Gretz S.S. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001;94(3):255–60.; Criscuolo C.M. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep 2001;5(5):407–11.; Gobel H., Heinze A., Kuhn K.H. et al. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001;91:195–9.; Wheeler A.H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998;38(6):468–71.; Filippi G.M., Errico P., Santarelli R. et al. Botulinum A toxin effect on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400–4.; Silberstein S.D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacoter 2001;2:1649–54.; Brin M.F., Fahn S., Moskowitz C. et al. Localized in ections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599–608.; Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve 1997;20:146–68.; Smuts J.A., Schultz D., Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004;44(8):801–5.; Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26(5):785–93.; Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107(1–2):125–33.; Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005;63:180–5.; Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51(10):1573–7.; Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122(3):315–25.; Gazerani P., Pedersen N.S., Staahl C. et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141(1–2):60–9.; Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000;59(11):1403–6.; Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38(2):245–58.; Артеменко А.Р., Орлова О.Р. Ботулинический токсин типа А: расширение возможностей терапии первичных головных болей. Врач 2007;5:40–3.; Куренков А.Л., Артеменко А.Р., Никитин С.С., Орлова О.Р. Современные представления о механизмах действия ботулинического токсина типа А. Врач 2009;7:8–12.; Cernuda-Morollón E., Larrosa D., Ramón C. et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013 [В печати].; Aurora S.K., Winner P., Freeman M.C. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56- week PREEMPT clinical program. Headache 2011;51:1358–73.; Drinovac V., Bach-Rojecky L., Matak I., Lacković Z. Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 2013;70:331–7.; Mathew N.T., Frishberg B.M., Gawel M. et al. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293–307.; Silberstein S.D., Stark S.R., Lucas S.M. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:1126–37.; https://nmb.abvpress.ru/jour/article/view/61
-
6Academic Journal
Authors: ЛЕПЕЙКО ЮЛИЯ БОРИСОВНА, НЕВЗОРОВА ВЕРА АФАНАСЬЕВНА, ГИЛИФАНОВ ЕВГЕНИЙ АЛЬБЕРТОВИЧ, ПАВЛУШ ДМИТРИЙ ГЕОРГИЕВИЧ, ДЮЙЗЕН ИНЕССА ВАЛЕРЬЕВНА
Subject Terms: СЛИЗИСТАЯ ОБОЛОЧКА ВЕРХНИХ ДЫХАТЕЛЬНЫХ ПУТЕЙ,ХРОНИЧЕСКОЕ ТАБАКОКУРЕНИЕ,НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ,ВЕЩЕСТВО Р,НЕЙРОКИНИНОВЫЕ РЕЦЕПТОРЫ
File Description: text/html
-
7Academic Journal
Authors: КРИВОНОСОВА Г.М., ЛЕГОНЬКОВА Т.И., КОСЕНКОВА Т.В.
Subject Terms: БРОНХИАЛЬНАЯ АСТМА, НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ, НЕЙРОПЕПТИДЫ, СУБСТАНЦИЯ Р, ВАЗОАКТИВНЫЙ ИНТЕСТИНАЛЬНЫЙ ПЕТИД
File Description: text/html
-
8Academic Journal
Authors: Погорелов, В.
Subject Terms: КОМОРБИДНЫЙ СИНДРОМ,НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ И РАДИКУЛОИШЕМИЯ,ДЕЗАГРЕГАНТНАЯ И МЕТАБОЛИЧЕСКАЯ ТЕРАПИЯ
File Description: text/html
-
9Academic Journal
Authors: Погорелов, В. В.
Subject Terms: медицина, хирургия, мельдоний, коморбидный синдром, нейрогенное воспаление, радикулоишемия, дезагрегантная терапия, метаболическая терапия
Availability: http://dspace.bsu.edu.ru/handle/123456789/58700
-
10Academic Journal
Authors: Артеменко, А., Куренков, А., Никитин, С., Беломестова, К.
Subject Terms: ХРОНИЧЕСКАЯ МИГРЕНЬ, БОТУЛИНИЧЕСКИЙ ТОКСИН ТИПА А, ОNABOTULINUMTOXINA, ХЕМОДЕНЕРВАЦИЯ, АНТИНОЦИЦЕПТИВНОЕ ДЕЙСТВИЕ, КАЛИЦИТОНИН-ГЕНСВЯЗАННЫЙ ПЕПТИД, НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ, ПЕРИФЕРИЧЕСКАЯ СЕНСИТИЗАЦИЯ, ЦЕНТРАЛЬНАЯ СЕНСИТИЗАЦИЯ, ДИСФУНКЦИЯ КРАНИОЦЕРВИКАЛЬНЫХ МЫШЦ, МЫШЕЧНЫЕ НОЦИЦЕПТОРЫ, ПАРАДИГМА PREEMPT, ПРИСТУП МИГРЕНИ, ПРОФИЛАКТИЧЕСКОЕ ЛЕЧЕНИЕ, СЕНСОРНЫЕ ВОЛОКНА ТРИГЕМИНАЛЬНОЙ СИСТЕМЫ
File Description: text/html
-
11Academic Journal
Authors: Орлова, Е., Молотилов, Б.
Subject Terms: КРАПИВНИЦА, СУБСТАНЦИЯ Р, НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ, НЕЙРОПЕПТИДЫ
File Description: text/html
-
12Academic Journal
Source: Современные проблемы науки и образования.
Subject Terms: БРОНХИАЛЬНАЯ АСТМА, НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ, НЕЙРОПЕПТИДЫ, СУБСТАНЦИЯ Р, ВАЗОАКТИВНЫЙ ИНТЕСТИНАЛЬНЫЙ ПЕТИД, 3. Good health
File Description: text/html
-
13Academic Journal
Source: Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация.
Subject Terms: КОМОРБИДНЫЙ СИНДРОМ,НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ И РАДИКУЛОИШЕМИЯ,ДЕЗАГРЕГАНТНАЯ И МЕТАБОЛИЧЕСКАЯ ТЕРАПИЯ
File Description: text/html
-
14Academic Journal
Source: Нервно-мышечные болезни.
Subject Terms: ХРОНИЧЕСКАЯ МИГРЕНЬ, БОТУЛИНИЧЕСКИЙ ТОКСИН ТИПА А, ОNABOTULINUMTOXINA, ХЕМОДЕНЕРВАЦИЯ, АНТИНОЦИЦЕПТИВНОЕ ДЕЙСТВИЕ, КАЛИЦИТОНИН-ГЕНСВЯЗАННЫЙ ПЕПТИД, НЕЙРОГЕННОЕ ВОСПАЛЕНИЕ, ПЕРИФЕРИЧЕСКАЯ СЕНСИТИЗАЦИЯ, ЦЕНТРАЛЬНАЯ СЕНСИТИЗАЦИЯ, ДИСФУНКЦИЯ КРАНИОЦЕРВИКАЛЬНЫХ МЫШЦ, МЫШЕЧНЫЕ НОЦИЦЕПТОРЫ, ПАРАДИГМА PREEMPT, ПРИСТУП МИГРЕНИ, ПРОФИЛАКТИЧЕСКОЕ ЛЕЧЕНИЕ, СЕНСОРНЫЕ ВОЛОКНА ТРИГЕМИНАЛЬНОЙ СИСТЕМЫ, 3. Good health
File Description: text/html
-
15Academic Journal
Source: Практическая медицина.
File Description: text/html
-
16Academic Journal
Authors: Сидоренко Е.Е., Львов А.Н., Миченко А.В., Сидоренко О.А., Коленько Н.Г.
Source: Медицинский алфавит
Subject Terms: acne, itch, neuropeptides, Neurogenic inflammation, substance P, акне, зуд, нейропептиды, нейрогенное воспаление, субстанция Р
Availability: https://repository.rudn.ru/records/article/record/94858/
